|
1
|
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He
JX, Liu L, Shan H, Lei CL, Hui DSC, et al: China medical treatment
expert group for Covid-19: Clinical characteristics of coronavirus
disease 2019 in China. N Engl J Med. 382:1708–1720. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J,
Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical characteristics
of 138 hospitalized patients with 2019 novel coronavirus-infected
pneumonia in Wuhan, China. JAMA. 323(1061)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Burnham EL, Janssen WJ, Riches DWH, Moss M
and Downey GP: The fibroproliferative response in acute respiratory
distress syndrome: Mechanisms and clinical significance. Eur Respir
J. 43:276–285. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cardinal-Fernández P, Lorente JA,
Ballén-Barragán A and Matute-Bello G: Acute respiratory distress
syndrome and diffuse alveolar damage. New insights on a complex
relationship. Ann Am Thorac Soc. 14:844–850. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Thille AW, Esteban A, Fernández-Segoviano
P, Rodriguez JM, Aramburu JA, Vargas-Errázuriz P, Martín-Pellicer
A, Lorente JA and Frutos-Vivar F: Chronology of histological
lesions in acute respiratory distress syndrome with diffuse
alveolar damage: A prospective cohort study of clinical autopsies.
Lancet Respir Med. 1:395–401. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
George PM, Wells AU and Jenkins RG:
Pulmonary fibrosis and COVID-19: the potential role for
antifibrotic therapy. Lancet Respir Med: https://doi.org/10.1016/S2213-2600(20)30225-3.
|
|
7
|
Huang X, Xiu H, Zhang S and Zhang G: The
role of macrophages in the pathogenesis of ALI/ARDS. Mediators
Inflamm. 2018(1264913)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S,
Huang H, Zhang L, Zhou X, Du C, et al: Risk factors associated with
acute respiratory distress syndrome and death in patients with
coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern
Med: doi:10.1001/jamainternmed.2020.0994.
|
|
9
|
Mo X, Jian W, Su Z, Chen M, Peng H, Peng
P, Lei C, Chen R, Zhong N and Li S: Abnormal pulmonary function in
COVID-19 patients at time of hospital discharge. Eur Respir J.
55(2001217)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hu Q, Guan H, Sun Z, Huang L, Chen C, Ai
T, Pan Y and Xia L: Early CT features and temporal lung changes in
COVID-19 pneumonia in Wuhan, China. Eur J Radiol.
128(109017)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wei J, Yang H, Lei P, Fan B, Qiu Y, Zeng
B, Yu P, Lv J, Jian Y and Wan C: Analysis of thin-section CT in
patients with coronavirus disease (COVID-19) after hospital
discharge. J XRay Sci Technol. 28:383–389. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ooi GC, Khong PL, Müller NL, Yiu WC, Zhou
LJ, Ho JC, Lam B, Nicolaou S and Tsang KW: Severe acute respiratory
syndrome: Temporal lung changes at thin-section CT in 30 patients.
Radiology. 230:836–844. 2004.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang P, Li J, Liu H, Han N, Ju J, Kou Y,
Chen L, Jiang M, Pan F, Zheng Y, et al: Long-term bone and lung
consequences associated with hospital-acquired severe acute
respiratory syndrome: A 15-year follow-up from a prospective cohort
study. Bone Res. 8(8)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Das KM, Lee EY, Singh R, Enani MA, Al
Dossari K, Van Gorkom K, Larsson SG and Langer RD: Follow-up chest
radiographic findings in patients with MERS-CoV after recovery.
Indian J Radiol Imaging. 27:342–349. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Meduri GU, Headley S, Kohler G, Stentz F,
Tolley E, Umberger R and Leeper K: Persistent elevation of
inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1
beta and IL-6 levels are consistent and efficient predictors of
outcome over time. Chest. 107:1062–1073. 1995.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Masclans JR, Roca O, Muñoz X, Pallisa E,
Torres F, Rello J and Morell F: Quality of life, pulmonary
function, and tomographic scan abnormalities after ARDS. Chest.
139:1340–1346. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Desai SR, Wells AU, Rubens MB, Evans TW
and Hansell DM: Acute respiratory distress syndrome: CT
abnormalities at long-term follow-up. Radiology. 210:29–35.
1999.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Burnham EL, Hyzy RC, Paine R III, Coley C
II, Kelly AM, Quint LE, Lynch D, Janssen WJ, Moss M and Standiford
TJ: Chest CT features are associated with poorer quality of life in
acute lung injury survivors. Crit Care Med. 41:445–456.
2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Spagnolo P, Balestro E, Aliberti S,
Cocconcelli E, Biondini D, Casa GD, Sverzellati N and Maher TM:
Pulmonary fibrosis secondary to COVID-19: A call to arms? Lancet
Respir Med: May 15, 2020 (Epub ahead of print).
|
|
20
|
Risitano AM, Mastellos DC, Huber-Lang M,
Yancopoulou D, Garlanda C, Ciceri F and Lambris JD: Complement as a
target in COVID-19? Nat Rev Immunol. 20:343–344. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Giamarellos-Bourboulis EJ, Netea MG,
Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, Damoraki G,
Gkavogianni T, Adami ME, Katsaounou P, et al: Complex immune
dysregulation in COVID-19 patients with severe respiratory failure.
Cell Host Microbe. 27:992–1000.e3. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yan L, Zhang H-T, Goncalves J, Xiao Y,
Wang M, Guo Y, Sun C, Tang X, Jing L, Zhang M, et al: An
interpretable mortality prediction model for COVID-19 patients. Nat
Mach Intell. 2:283–288. 2020.
|
|
23
|
Kishaba T, Tamaki H, Shimaoka Y, Fukuyama
H and Yamashiro S: Staging of acute exacerbation in patients with
idiopathic pulmonary fibrosis. Lung. 192:141–149. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang Y, Wang H, Zhang C, Zhang C, Yang H,
Gao R and Tong Z: Lung fluid biomarkers for acute respiratory
distress syndrome: A systematic review and meta-analysis. Crit
Care. 23(43)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Capelozzi VL, Allen TC, Beasley MB, Cagle
PT, Guinee D, Hariri LP, Husain AN, Jain D, Lantuejoul S, Larsen
BT, et al: Molecular and Immune Biomarkers in Acute Respiratory
Distress Syndrome: A Perspective From Members of the Pulmonary
Pathology Society. Arch Pathol Lab Med. 141:1719–1727.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Madtes DK, Rubenfeld G, Klima LD, Milberg
JA, Steinberg KP, Martin TR, Raghu G, Hudson LD and Clark JG:
Elevated transforming growth factor-α levels in bronchoalveolar
lavage fluid of patients with acute respiratory distress syndrome.
Am J Respir Crit Care Med. 158:424–430. 1998.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Forel JM, Guervilly C, Hraiech S, Voillet
F, Thomas G, Somma C, Secq V, Farnarier C, Payan MJ, Donati SY, et
al: Type III procollagen is a reliable marker of ARDS-associated
lung fibroproliferation. Intensive Care Med. 41:1–11.
2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Quesnel C, Piednoir P, Gelly J, Nardelli
L, Garnier M, Leçon V, Lasocki S, Bouadma L, Philip I, Elbim C, et
al: Alveolar fibrocyte percentage is an independent predictor of
poor outcome in patients with acute lung injury. Crit Care Med.
40:21–28. 2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lin CM, Alrbiaan A, Odackal J, Zhang Z,
Scindia Y, Sung SJ, Burdick MD and Mehrad B: Circulating fibrocytes
traffic to the lung in murine acute lung injury and predict
outcomes in human acute respiratory distress syndrome: A pilot
study. Mol Med. 26(52)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tsitoura E, Bibaki E, Bolaki M, Vasarmidi
E, Trachalaki A, Symvoulakis EK, Spandidos DA and Antoniou MK:
[Comment] Treatment strategies to fight the new coronavirus
SARS-CoV-2: A challenge for a Rubik's Cube solver. Exp Ther Med.
20:147–150. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Margaritopoulos GA, Trachalaki A, Wells
AU, Vasarmidi E, Bibaki E, Papastratigakis G, Detorakis S, Tzanakis
N and Antoniou KM: Pirfenidone improves survival in IPF: Results
from a real-life study. BMC Pulm Med. 18(177)2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Antoniou K, Markopoulou K, Tzouvelekis A,
Trachalaki A, Vasarmidi E, Organtzis J, Tzilas V, Bouros E, Kounti
G, Rampiadou C, et al: Efficacy and safety of nintedanib in a Greek
multicentre idiopathic pulmonary fibrosis registry: A
retrospective, observational, cohort study. ERJ Open Res.
6:00172–02019. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Shi H, Han X, Jiang N, Cao Y, Alwalid O,
Gu J, Fan Y and Zheng C: Radiological findings from 81 patients
with COVID-19 pneumonia in Wuhan, China: A descriptive study.
Lancet Infect Dis. 20:425–434. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Li Y, Li H, Liu S, Pan P, Su X, Tan H, Wu
D, Zhang L, Song C, Dai M, et al: Pirfenidone ameliorates
lipopolysaccharide-induced pulmonary inflammation and fibrosis by
blocking NLRP3 inflammasome activation. Mol Immunol. 99:134–144.
2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Saha A, Vaidya PJ, Chavhan VB, Achlerkar
A, Leuppi JD and Chhajed PN: Combined pirfenidone, azithromycin and
prednisolone in post-H1N1 ARDS pulmonary fibrosis. Sarcoidosis Vasc
Diffuse Lung Dis. 35:85–90. 2018.PubMed/NCBI View Article : Google Scholar
|
